Fungiplex® Aspergillus PCR CE/IVD
X
You are enquiring about Fungiplex® Aspergillus PCR CE/IVD
Molecular testing for Aspergillus
Fungiplex Aspergillus is a real-time PCR designed to detect the main species associated with IA, and differentiates species resistant to first-line treatment:
Aspergillus spp. (A. fumigatus, A. flavus, A. niger)
A. terreus
Direct testing
Fungiplex Aspergillus is suitable for the routine testing of patients at-risk of IA, and is compatible with samples taken for other biomarker tests:
Validated on DNA extracted from whole blood, serum, plasma
Validated on DNA extracted from bronchoalveolar lavage (BAL) fluid
Rapid results
Fungiplex Aspergillus provides results in under 2 hours from extracted DNA, helping the laboratory to support clinical decision-making when time matters.
Compatibility
Fungiplex Aspergillus is provided in an easy to use master-mix format and is designed to run on existing laboratory equipment, minimising the need for dedicated bench space or additional training:
ABI 7500
ABI QuantStudio 5
Bio-Rad CFX
Hain FluoroCycler XT
Mic qPCR Cycler
Roche Lightcycler 480 II
Qiagen RotorGene
Invasive Aspergillosis
Invasive Aspergillosis (IA) is a life threatening condition, which affects immuno-compromised patients, such as those undergoing haematopoeitic stem cell transplantation. Difficult to Diagnose, IA is associated with high mortality. Rapid, reliable diagnostic tests for Aspergillus, when incorporated into patient care pathways, allow for the targeted use of antifungal therapy.
Clinical problem
Invasive Aspergillosis is difficult to diagnose. Traditional techniques have poor clinical sensitivity and tend towards positivity late in disease. Delays in diagnosis by conventional techniques, such as culture and histology, have lead to the widespread use of prophylaxis and empiric treatment in the management of IA. Rapid, reliable diagnostics support physicians in the timely treatment of patients with appropriate therapy; reducing the use of anti-fungal drugs, without adversely affecting patient outcomes.¹²
IA is hard to diagnose with non-specific symptoms and poor culture sensitivity
Delayed diagnosis is associated with high mortality and morbidity
The use of prophylaxis and emiric treatment is widespread
The inclusion of PCR in regular biomarker testing strategies for the diagnosis of Invasive Aspergillosis can:
Reduce the time to diagnosis
Reduce the use of empiric therapy
Reduce the cost of care
1. Barnes RA et al. 2009 J. Clin. Pathol. 62: 64-60. doi: 10.1136/jcp.2008.058354
2. Morrissey CO et al. 2013 Lancet Infect. Dis. 13: 519-528. doi: 10.1016/S1473-3099(13)70076-8
Fungiplex Aspergillus is a real-time PCR designed to detect the main species associated with IA, and differentiates species resistant to first-line treatment:
Aspergillus spp. (A. fumigatus, A. flavus, A. niger)
A. terreus
Direct testing
Fungiplex Aspergillus is suitable for the routine testing of patients at-risk of IA, and is compatible with samples taken for other biomarker tests:
Validated on DNA extracted from whole blood, serum, plasma
Validated on DNA extracted from bronchoalveolar lavage (BAL) fluid
Rapid results
Fungiplex Aspergillus provides results in under 2 hours from extracted DNA, helping the laboratory to support clinical decision-making when time matters.
Compatibility
Fungiplex Aspergillus is provided in an easy to use master-mix format and is designed to run on existing laboratory equipment, minimising the need for dedicated bench space or additional training:
ABI 7500
ABI QuantStudio 5
Bio-Rad CFX
Hain FluoroCycler XT
Mic qPCR Cycler
Roche Lightcycler 480 II
Qiagen RotorGene
Invasive Aspergillosis
Invasive Aspergillosis (IA) is a life threatening condition, which affects immuno-compromised patients, such as those undergoing haematopoeitic stem cell transplantation. Difficult to Diagnose, IA is associated with high mortality. Rapid, reliable diagnostic tests for Aspergillus, when incorporated into patient care pathways, allow for the targeted use of antifungal therapy.
Clinical problem
Invasive Aspergillosis is difficult to diagnose. Traditional techniques have poor clinical sensitivity and tend towards positivity late in disease. Delays in diagnosis by conventional techniques, such as culture and histology, have lead to the widespread use of prophylaxis and empiric treatment in the management of IA. Rapid, reliable diagnostics support physicians in the timely treatment of patients with appropriate therapy; reducing the use of anti-fungal drugs, without adversely affecting patient outcomes.¹²
IA is hard to diagnose with non-specific symptoms and poor culture sensitivity
Delayed diagnosis is associated with high mortality and morbidity
The use of prophylaxis and emiric treatment is widespread
The inclusion of PCR in regular biomarker testing strategies for the diagnosis of Invasive Aspergillosis can:
Reduce the time to diagnosis
Reduce the use of empiric therapy
Reduce the cost of care
1. Barnes RA et al. 2009 J. Clin. Pathol. 62: 64-60. doi: 10.1136/jcp.2008.058354
2. Morrissey CO et al. 2013 Lancet Infect. Dis. 13: 519-528. doi: 10.1016/S1473-3099(13)70076-8
| Is Featured? | No |
|---|
Write Your Own Review